Posted by Michael Wonder on 06 May 2023
Glaukos announces FDA acceptance of NDA submission for iDose TR
5 May 2023 - PDUFA date set for 22 December 2023.
Glaukos Corporation today announced it has received the “Day 74” notification from the US FDA acknowledging the previously submitted new drug application for iDose TR (travoprost intraocular implant) is sufficiently complete to permit a substantive review.
